NICE adds final new option on Roche's MabThera for advanced follicular lymphoma
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has said today in final and binding guidance that Roche's MabThera (rituximab) can be used alongside chlorambucil to treat patients with advanced follicular lymphoma. The dual therapy comes on top of four new MabThera regimens detailed in previous draft guidance.